Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

7.570 +0.100 (+1.34%)
Official Closing Price Updated: 4:15 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Altimmune Inc

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio 
Via MarketBeat
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market 
Via MarketBeat
Exposures Product Safety
7 Stocks That Will Drive the Weight Loss Drugs Market
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis. 
Via MarketBeat
Altimmune Inc. (NASDAQ: ALT) is One of Thursday Morning’s Most Active Stocks
Via Investor Brand Network
Altimmune Inc. (NASDAQ: ALT) is One of Friday Morning’s Most Active Stocks
Via Investor Brand Network
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,... 
Via NewMediaWire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,... 
Via TheNewswire.com
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - March 01, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,... 
Via TheNewswire.com
ALT LOSS ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ALT LOSS ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - February 27, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,... 
Via TheNewswire.com
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - February 20, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of... 
Via TheNewswire.com
NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
From The Rosen Law Firm, P.A.
Via Business Wire
2 biotechs with promising weight-loss drugs coming
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. 
Via MarketBeat
Weight Watchers gains from Oprah’s GLP-1 weight-loss
Oprah Winfrey revealed she has lost over 60 pounds and is on the path to reaching her weight goal of 167 lbs. She credits this to taking GLP-1 medication 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. 
Via MarketBeat
MarketBeat Week in Review: 12/11 - 12/15
The rally in stocks moved into high gear on hopes for interest rate hikes next year; conditions are right for the rally to continue into 2024. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Can Altimmune's weight-loss drug be a game-changer?
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold 
Via MarketBeat
Exposures Product Safety
PRISM MarketView Highlights Altimmune’s Positive Topline Results in Obesity Drug Trial
Via AB Newswire
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP 
Via MarketBeat
California and NYC Order Mandatory COVID-19 Testing Among Municipal Workers
Via FinancialNewsMedia
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.